These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 15310270

  • 21. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [Abstract] [Full Text] [Related]

  • 22. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
    de Beer F, van Dijk KW, Jong MC, van Vark LC, van der Zee A, Hofker MH, Fallaux FJ, Hoeben RC, Smelt AH, Havekes LM.
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
    [Abstract] [Full Text] [Related]

  • 23. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia.
    Sacks FM.
    Curr Opin Lipidol; 2015 Feb; 26(1):56-63. PubMed ID: 25551803
    [Abstract] [Full Text] [Related]

  • 24. Changes in plasma lipoproteins during lipolysis in vivo in the hypertriglyceridemic state.
    Karakas SE, Khilnani S, Divens C, Almario R, Jen KL.
    Am J Clin Nutr; 1994 Feb; 59(2):378-83. PubMed ID: 8310988
    [Abstract] [Full Text] [Related]

  • 25. Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins.
    Chung BH, Tallis G, Yalamoori V, Anantharamaiah GM, Segrest JP.
    Arterioscler Thromb; 1994 Apr; 14(4):622-35. PubMed ID: 8148360
    [Abstract] [Full Text] [Related]

  • 26. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice.
    Kypreos KE, Morani P, van Dijk KW, Havekes LM, Zannis VI.
    Biochemistry; 2001 May 22; 40(20):6027-35. PubMed ID: 11352738
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of lipoprotein lipase induced cholesterol ester accumulation in human hepatoma HepG2 cells.
    Cianflone K, Avramoglu RK, Sawyez C, Huff MW.
    Atherosclerosis; 1996 Feb 22; 120(1-2):101-14. PubMed ID: 8645351
    [Abstract] [Full Text] [Related]

  • 28. Receptor-mediated mechanisms of lipoprotein remnant catabolism.
    Chappell DA, Medh JD.
    Prog Lipid Res; 1998 Dec 22; 37(6):393-422. PubMed ID: 10209655
    [Abstract] [Full Text] [Related]

  • 29. A case of moderate hypertriglyceridemia with apolipoprotein E phenotype E4/3.
    Kojima S, Homma Y, Sakane H, Kobayashi T, Ozawa H, Okajima Y.
    Tokai J Exp Clin Med; 1996 Dec 22; 21(4-6):165-9. PubMed ID: 9300976
    [Abstract] [Full Text] [Related]

  • 30. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.
    Zheng C, Khoo C, Ikewaki K, Sacks FM.
    J Lipid Res; 2007 May 22; 48(5):1190-203. PubMed ID: 17314277
    [Abstract] [Full Text] [Related]

  • 31. Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma.
    Fan J, Ji ZS, Huang Y, de Silva H, Sanan D, Mahley RW, Innerarity TL, Taylor JM.
    J Clin Invest; 1998 May 15; 101(10):2151-64. PubMed ID: 9593771
    [Abstract] [Full Text] [Related]

  • 32. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
    Marais AD.
    Pathology; 2019 Feb 15; 51(2):165-176. PubMed ID: 30598326
    [Abstract] [Full Text] [Related]

  • 33. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.
    MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, Esko JD.
    J Clin Invest; 2007 Jan 15; 117(1):153-64. PubMed ID: 17200715
    [Abstract] [Full Text] [Related]

  • 34. Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels.
    Wang L, Shearer GC, Budamagunta MS, Voss JC, Molfino A, Kaysen GA.
    Kidney Int; 2012 Nov 15; 82(9):990-9. PubMed ID: 22785171
    [Abstract] [Full Text] [Related]

  • 35. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice.
    Chroni A, Kan HY, Kypreos KE, Gorshkova IN, Shkodrani A, Zannis VI.
    Biochemistry; 2004 Aug 17; 43(32):10442-57. PubMed ID: 15301543
    [Abstract] [Full Text] [Related]

  • 36. Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles.
    Pedreño J, Hurt-Camejo E, Wiklund O, Badimón L, Masana L.
    Metabolism; 2000 Jul 17; 49(7):942-9. PubMed ID: 10910008
    [Abstract] [Full Text] [Related]

  • 37. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.
    Wang CS, Alaupovic P, Gregg RE, Brewer HB.
    Biochim Biophys Acta; 1987 Jul 13; 920(1):9-19. PubMed ID: 3109493
    [Abstract] [Full Text] [Related]

  • 38. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
    Ebara T, Ramakrishnan R, Steiner G, Shachter NS.
    J Clin Invest; 1997 Jun 01; 99(11):2672-81. PubMed ID: 9169497
    [Abstract] [Full Text] [Related]

  • 39. Decreased Efficiency of Very-Low-Density Lipoprotein Lipolysis Is Linked to Both Hypertriglyceridemia and Hypercholesterolemia, but It Can Be Counteracted by High-Density Lipoprotein.
    Wieczorek E, Ćwiklińska A, Kuchta A, Kortas-Stempak B, Gliwińska A, Jankowski M.
    Nutrients; 2021 Apr 08; 13(4):. PubMed ID: 33917704
    [Abstract] [Full Text] [Related]

  • 40. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease.
    Karpe F, Hellénius ML, Hamsten A.
    Metabolism; 1999 Mar 08; 48(3):301-7. PubMed ID: 10094104
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.